PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists

Core Insights - PharmAla Biotech Holdings Inc. has launched NEXUS, a new tool aimed at connecting prescribers, therapists, and clinic managers involved in MDMA-assisted therapy, enhancing the care delivery process [1][2][3] Group 1: NEXUS Tool - NEXUS is designed to facilitate communication and data sharing among the entire MDMA-assisted therapy team, including prescribers, therapists, and clinic managers [2][3] - The tool aims to address the challenges faced by prescribers and other stakeholders in navigating regulatory pathways and improving patient care [2][3] Group 2: Leadership Changes - Farnoud Kazemzadeh has been appointed as the Chief Operating Officer of PharmAla, bringing extensive experience in scaling businesses [3] - Dr. Harriet De Wit has resigned from PharmAla's Board of Directors, with the company expressing gratitude for her contributions [4] Group 3: Company Overview - PharmAla focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company providing clinical-grade MDMA for patient treatments outside of clinical trials [5] - The company aims to alleviate the backlog of clinical-grade MDMA for trials and commercial sales while developing novel drugs in the same class [5]